- Home
- TARA vs PRQR Comparison
TARA vs PRQR Comparison
Compare TARA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | PRQR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 262.5M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TARA | PRQR |
|---|---|---|
| Price | $3.97 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $24.40 | $7.25 |
| AVG Volume (30 Days) | 337.6K | ★ 917.4K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $1.33 |
| 52 Week High | $7.82 | $3.10 |
Technical Indicators
Market Signals| Indicator | TARA | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 66.93 |
| Support Level | $3.73 | $1.40 |
| Resistance Level | $4.17 | $2.44 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 59.78 | 78.36 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.